A few reports have suggested that β2AR activation can increase Aβ and tau pathology via regulating the internalization of surface APP molecules and/or γ‐secretase activity, thereby increasing Aβ production, leading to a recommendation of using β‐blockers such as propranolol in the clinical management of AD (Ni et al, 2006; Dobarro et al, 2013; Wang et al, 2013). Here, ADRB2 is linked to Alzheimer disease.